We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
51039 676 3 BTK
Emcee:  Biomaven Type:  Moderated
Biotech stocks are a close second only to internet stocks in how difficult they are to objectively value. This means that biotech stocks can be wildly under- or over-valued, which creates an opportunity for either profit or frustration for an investor that "knows better than market." To paraphrase the master: "Every now and again you should look at the stock price to see if the market is offering to do anything stupid."

This thread grew out of the "Munch-a-Biotech" thread, and is meant to discuss biotech stock valuation methods of all sorts, as well as particular stocks or sectors you may feel are under- or over-valued.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51039A valuation case study..... sickeconomics.comSickEconomist-Saturday
51038>>Not sure how revenues flow to FGEN from the chinese entity though. It&#Biomaven-last Friday
51037I guess the needle might get moved if the gov't decides to pay for DD and/oratticus4paws-last Thursday
51036China approves Roxadustat for chronic kidney disease(CKD, including non-dialysisA.J. Mullen1last Wednesday
51035China adds 148 drugs to key insurance list: state media BEIJING/SHANGHAI (Reutejb118-last Wednesday
51034UCSF has some high profile clinicians who also publish/run trials, teach etc Broldirtybastard-last Monday
51033SESN-Sesen Bio: One Step Closer To FDA Approval - An Update seekingalpha.comCeltictrader-last Monday
51032GSK's dapro may in fact have a trial in NDD vs. PBO. It does: ASCEND-NHQ btuck-August 18
51031<<1. For the first time (i.e., the first quarterly report), FGEN reported quidditch3August 18
51030OT - need MS specialist in San Francisco. I have a young friend that is a likelIRWIN JAMES FRANKEL-August 17
51029CELG I'm starting to wonder if they will be able to sell Otezla. Seems likIRWIN JAMES FRANKEL-August 17
51028Struggle for power is devastating population effected with ebola, and individualMiljenko Zuanic-August 14
51027Recent weakness in the share price of Ionis Pharmaceuticals appears to be relateArt Bechhoefer-August 14
51026Much needed in some places: reuters.comnigel bates-August 14
51025Indeed, “Now we can say that 90 percent can come out of treatment cured, they wiMiljenko Zuanic-August 13
51024Good news re Ebola: nytimes.comnigel bates-August 13
51023"That would seem to open them up for all the other indications like Cancer Art Bechhoefer-August 12
51022That would seem to open them up for all the other indications like Cancer anemiaJamesK-August 10
51021I'm still scratching my head regarding comparing roxadust against a placebo A.J. Mullen-August 9
51020Buying anything in this market is getting dangerous, owing mainly to concerted pArt Bechhoefer-August 9
51019The call seemed clearer than the last one and pretty positive. Was that your inCpi3663-August 9
51018FGEN pretty much came out and said not to worry about non-inferiority after theyBiomaven1August 8
51017Fibrogen's reported, 8k and call information, seekingalpha.comA.J. Mullen-August 8
51016>>Should we trust Basf? Yes, but very few have ever even heard of them. Biomaven-August 3
51015I agree that there is very low trust when come to bottle content, coming from AsMiljenko Zuanic-July 31
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):